Amgen Raises $200M to Propel Next-Generation Biotech Innovations and Transform Patient Care

Amgen is thrilled to announce that we have successfully raised $200,000,000 in our latest funding round—a significant milestone that propels our mission forward to harness the best of biology and technology in the fight against some of the world’s toughest diseases. As a pioneer in establishing the biotechnology industry, Amgen’s enduring commitment to research and development has continuously pushed the boundaries of science, innovation, and healthcare. These new funds will be strategically invested in expanding our robust pipeline of therapies targeting cancer, heart disease, osteoporosis, inflammatory diseases, and rare conditions, further strengthening our commitment to developing life-enhancing medicines. With our cutting-edge approach that leverages human genetic data and advanced technological tools, this investment empowers us to accelerate discovery and drive breakthroughs that make life easier, fuller, and longer for millions of people around the globe. As one of the 30 companies in the Dow Jones Industrial Average® and part of the Nasdaq-100 Index®, Amgen’s reputation for innovation and excellence is recognized worldwide. In 2024, our efforts were celebrated by Fast Company as one of the “World’s Most Innovative Companies” and by Forbes as one of “America’s Best Large Employers.” This funding milestone not only builds on our outstanding legacy in biotechnology but also solidifies our future as we continue to explore new frontiers in medicine. For additional details about our journey and our ongoing innovations, we invite you to visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube, and Threads.